Kymera Therapeutics (KYMR) News Today $43.70 +3.09 (+7.61%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Stephens Reaffirms Overweight Rating for Kymera Therapeutics (NASDAQ:KYMR)Stephens restated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday.January 21 at 12:52 PM | marketbeat.comKymera TherapeuticsJanuary 17, 2025 | forbes.comKymera Therapeutics: Strategic Advancements and Strong Financials Bolster Buy Rating by AnalystJanuary 17, 2025 | markets.businessinsider.comKymera Therapeutics (NASDAQ:KYMR) Trading Down 6.3% - Time to Sell?Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.3% - Should You Sell?January 16, 2025 | marketbeat.comBank of America Securities Remains a Hold on Kymera Therapeutics (KYMR)January 16, 2025 | markets.businessinsider.comJPMorgan Chase & Co. Acquires 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)JPMorgan Chase & Co. boosted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 212.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 140,491 shares of the company's stock afterJanuary 16, 2025 | marketbeat.comKymera stock surges on product pipeline updateJanuary 14, 2025 | in.investing.comKymera Therapeutics announces corporate goals for 2025January 14, 2025 | markets.businessinsider.comKymera Therapeutics (NASDAQ:KYMR) Shares Up 6.4% - Here's What HappenedKymera Therapeutics (NASDAQ:KYMR) Trading Up 6.4% - What's Next?January 14, 2025 | marketbeat.comKymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsJanuary 14, 2025 | globenewswire.comKymera Therapeutics: Promising Prospects with Targeted Protein Degradation and Innovative Drug KT-621January 8, 2025 | markets.businessinsider.comAnalysts Issue Forecasts for KYMR FY2029 EarningsKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at Brookline Capital Management issued their FY2029 EPS estimates for shares of Kymera Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will post eaJanuary 8, 2025 | marketbeat.comKymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14January 7, 2025 | globenewswire.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in StockKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Ellen Chiniara sold 3,129 shares of the firm's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.January 6, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by AnalystsKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eighteen ratings firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buyDecember 29, 2024 | marketbeat.comKymera Therapeutics' (KYMR) "Outperform" Rating Reiterated at Leerink PartnersLeerink Partners restated an "outperform" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday.December 27, 2024 | marketbeat.comLeerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken dealDecember 26, 2024 | markets.businessinsider.comState Street Corp Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)State Street Corp decreased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,728,144 shares of the company's stock after selling 182,547 shares duringDecember 17, 2024 | marketbeat.comBTIG Initiates Coverage of Kymera Therapeutics (KYMR) with Buy RecommendationDecember 11, 2024 | msn.comKymera Therapeutics (NASDAQ:KYMR) Now Covered by BTIG ResearchBTIG Research started coverage on Kymera Therapeutics in a research report on Tuesday. They set a "buy" rating and a $60.00 price objective on the stock.December 10, 2024 | marketbeat.comPositive Report for Kymera Therapeutics (KYMR) from Wells FargoDecember 9, 2024 | markets.businessinsider.comWellington Management Group LLP Has $218.59 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Wellington Management Group LLP boosted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 7.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,618,359 shares of the comDecember 9, 2024 | marketbeat.comTwo Sigma Advisers LP Sells 30,700 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Two Sigma Advisers LP cut its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 8.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 336,300 shares of the company's stock after sellingDecember 9, 2024 | marketbeat.comBMO Capital Initiates Coverage of Kymera Therapeutics (KYMR) with Market Perform RecommendationDecember 6, 2024 | msn.comBMO Capital Markets Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR)BMO Capital Markets started coverage on shares of Kymera Therapeutics in a report on Friday. They issued a "market perform" rating and a $55.00 target price for the company.December 6, 2024 | marketbeat.comKymera Therapeutics initiated with a Market Perform at BMO CapitalDecember 6, 2024 | markets.businessinsider.comCautious Optimism for Kymera Therapeutics: Hold Rating Amid Uncertainties in Innovative Protein Degradation ProgramsDecember 6, 2024 | markets.businessinsider.comKymera Therapeutics, Inc. (NASDAQ:KYMR) is Redmile Group LLC's 5th Largest PositionRedmile Group LLC lessened its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 11.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,393,256 shares of the company's stockDecember 5, 2024 | marketbeat.com25,000 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by Bamco Inc. NYBamco Inc. NY acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 25,000 shares of the company's stock, valued at approximately $1,183,000. A number of other institDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Makes New $1.32 Million Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Erste Asset Management GmbH acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,000 shares oDecember 4, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by BrokeragesKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, twelve have isDecember 4, 2024 | marketbeat.com12,743 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by HighVista Strategies LLCHighVista Strategies LLC bought a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,743 shares of theDecember 3, 2024 | marketbeat.comCinctive Capital Management LP Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Cinctive Capital Management LP purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 56,801 shares of the company's stock, valued at apprDecember 3, 2024 | marketbeat.comKymera Therapeutics upgraded to Overweight from Equal Weight at Wells FargoDecember 3, 2024 | markets.businessinsider.comWells Fargo Upgrades Kymera Therapeutics (KYMR)December 3, 2024 | msn.comFred Alger Management LLC Makes New $859,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Fred Alger Management LLC purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 18,141 shares of the company's stDecember 2, 2024 | marketbeat.comFmr LLC Has $241.82 Million Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Fmr LLC grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,109,141 shares of the company's stock after acquiring an additional 282,301 shares durDecember 2, 2024 | marketbeat.comIntech Investment Management LLC Makes New $650,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Intech Investment Management LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 13,727 shares of the company's stock, valued at approximatelyDecember 1, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Purchased by Eventide Asset Management LLCEventide Asset Management LLC increased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 507,902 shares of the company'November 29, 2024 | marketbeat.comNatixis Advisors LLC Purchases Shares of 14,378 Kymera Therapeutics, Inc. (NASDAQ:KYMR)Natixis Advisors LLC acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,378 shares of the company's stock, valuedNovember 28, 2024 | marketbeat.comKymera Therapeutics to Participate in Upcoming December Investor ConferencesNovember 26, 2024 | globenewswire.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA grew its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 11.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 453,377 shares of thNovember 26, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Acquired by Jennison Associates LLCJennison Associates LLC boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 85.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 797,681 shares of the companNovember 22, 2024 | marketbeat.comStephens & Co. Initiates Coverage of Kymera Therapeutics (KYMR) with Overweight RecommendationNovember 20, 2024 | msn.comKymera Therapeutics (NASDAQ:KYMR) Now Covered by StephensStephens assumed coverage on shares of Kymera Therapeutics in a research report on Monday. They issued an "overweight" rating and a $65.00 target price for the company.November 18, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7% - Here's What HappenedKymera Therapeutics (NASDAQ:KYMR) Trading Down 6.7% - Should You Sell?November 15, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, ten have aNovember 9, 2024 | marketbeat.comKymera Therapeutics price target raised to $49 from $45 at Morgan StanleyNovember 7, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)November 6, 2024 | markets.businessinsider.comKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00Morgan Stanley upped their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research note on Wednesday.November 6, 2024 | marketbeat.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.570.57▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼95▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News Today ROIV News Today ASND News Today BPMC News Today RVMD News Today BBIO News Today LNTH News Today LEGN News Today ELAN News Today CYTK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYMR Stock Alerts